Literature DB >> 16392897

BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays?

Sallyanne C Fossey1, Andrea Ferreira-Gonzalez, Carleton T Garrett, Catherine I Dumur, Cindy L Vnencak-Jones.   

Abstract

BACKGROUND: Quantitative real-time PCR has become the predominant molecular technique to monitor BCRABL levels in response to treatment in Ph(+) leukemia patients. However, without some form of standardized methodology between laboratories, the correlation of results is difficult.
METHODS: Using TaqMan-based assays, parallel quantitative real-time PCR analysis was performed on 70 clinical specimens at Vanderbilt University Medical Center and Virginia Commonwealth University. While the same positive control cell line (K562) and quality control gene (BCR) were used, the RNA isolation technique, cDNA synthesis, BCR control cell line, and PCR primer and probe sequences were different.
RESULTS: The detection of BCRABL-positive results spanned a dynamic range from 10(0) to 10(5)/100,000 cells. Forty-three samples were negative at both facilities. A Spearman rank correlation analysis was performed for the 22 BCRABL-positive paired results. The correlation coefficient, r(s), was 0.9435 (p < 0.00001), suggesting a strong correlation of the results. One discordant result was obtained for consecutive samples from one patient with a low BCRABL copy number as a result of a minimal RNA yield at one laboratory.
CONCLUSIONS: These results suggest that quantitative real-time PCR assays for BCRABL detection can be comparable between laboratories despite significant differences in methodologies if the same positive control cell line and quality control gene are used. It is imperative that some level of assay standardization be adopted between laboratories, not only for patients who are monitored at different facilities, but also for larger investigative studies in which hematologic, cytogenetic and molecular responses are to be compared.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16392897     DOI: 10.1007/BF03260090

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  19 in total

1.  Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization.

Authors:  S Naumann; D Reutzel; M Speicher; H J Decker
Journal:  Leuk Res       Date:  2001-04       Impact factor: 3.156

Review 2.  Chronic myeloid leukemia--advances in biology and new approaches to treatment.

Authors:  John M Goldman; Junia V Melo
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

3.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.

Authors:  S Branford; T P Hughes; Z Rudzki
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

6.  Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-562.

Authors:  S Q Wu; K V Voelkerding; L Sabatini; X R Chen; J Huang; L F Meisner
Journal:  Leukemia       Date:  1995-05       Impact factor: 11.528

7.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

8.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

9.  Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR.

Authors:  E Mensink; A van de Locht; A Schattenberg; E Linders; N Schaap; A Geurts van Kessel; T De Witte
Journal:  Br J Haematol       Date:  1998-08       Impact factor: 6.998

10.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.